Bachem Holding AG stock (CH0012530207): Peptide leader eyes US biotech growth

Bachem Holding AG maintains its role as a key supplier of custom peptides for the global pharmaceutical industry. The company reported steady contract manufacturing growth in its latest updates, with a focus on US-based biotech clients driving revenue. Shares have shown resilience amid sector volatility, trading around recent levels on the SIX Swiss Exchange.

The stock traded at 76.50 CHF on 05/12/2026 on SIX Swiss Exchange, according to SIX Group as of 05/12/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Bachem Holding AG: core business model

Bachem Holding AG specializes in the development and manufacture of peptides and complex biomolecules for pharmaceutical and biotech applications. Founded in 1971, the company operates production sites in Switzerland, the US, UK, and Germany, adhering to GMP standards. Its catalog and custom peptide services support research, clinical trials, and commercial production worldwide, according to Bachem IR as of 05/2026.

The business model centers on long-term contracts with pharma giants and emerging biotechs, providing a stable revenue stream. Bachem's expertise in solid-phase peptide synthesis positions it as a preferred partner for GLP-1 agonists and other high-value therapeutics gaining traction in the US market.

Main revenue and product drivers for Bachem Holding AG

Revenue primarily stems from custom synthesis (over 60% of sales) and catalog products, with the US accounting for about 40% of group revenue per the 2024 annual report published March 2025. Key drivers include demand for peptides in obesity treatments and oncology drugs. North American operations, bolstered by the 2021 acquisition of American Peptide Company, have ramped up capacity, according to Bachem annual report as of 03/25/2025.

Growth in GLP-1 related projects and peptide APIs for generics supports mid-single-digit organic expansion. The company's investment in US facilities enhances its appeal to American biotech firms navigating supply chain localization trends.

Industry trends and competitive position

The peptide therapeutics market is projected to grow at 8-10% CAGR through 2030, driven by peptide-based drugs for metabolic and cancer indications, per Evaluate Pharma as of 01/2026. Bachem competes with Lonza, PolyPeptide Group, and smaller CMOs but leads in custom peptide scale-up capabilities.

Its US presence gives Bachem an edge for FDA-focused clients, reducing transatlantic logistics risks amid ongoing supply chain scrutiny.

Why Bachem Holding AG matters for US investors

Bachem Holding AG offers US investors exposure to the booming peptide segment of biotech without direct R&D risk. Listed on SIX, its ADRs trade OTC, providing easy access. The company's heavy US revenue reliance ties its fortunes to American drug innovation pipelines.

Conclusion

Bachem Holding AG stands as a reliable player in peptide manufacturing, with US expansion fueling growth prospects. Steady contract wins and capacity builds underpin its market position, though execution in competitive bids remains key. Investors track its performance amid broader biotech funding cycles.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.